18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography

R. L. Wahl, Gary Hutchins, D. J. Buchsbaum, M. Liebert, H. Barton Grossman, S. Fisher

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

The positron-emitting glucose analogue 18F-2-fluoro-2-deoxy-d-glucose (FDG) was evaluated for its accretion into the following subcutaneous human tumor xenografts in nude mice: B-cell lymphoma (Namalwa or Raji), ovarian carcinoma (HTB77), colon cancer (SW948), choriocarcinoma (BEWO), bladder cancer (UM-UC-2), renal cell carcinoma (UM-RC-3), neuroblastoma (Mey), melanoma (HTB63), and small cell lung carcinoma (NCI69). Two hours postinjection, tumor uptakes ranged from 0.027 (colon cancer) to 0.125% kg injected dose/g (melanoma); and was greater than 0.085 in the Namalwa lymphomas and the renal cell carcinomas. Tumor-blood ratios of up to 23:1 were seen 2 hours postinjection (melanoma) with a mean tumor-blood ratio for all tumors of 12.3 ± 1.8. Uptake in the other tumors was intermediate. When evaluated, tumor uptake was slightly greater at 1 than at 2 hours postinjection, although target-background ratios were generally higher at 2 hours postinjection. This compound, FDG, may have broad applicability as a tracer for positron-emission tomographic imaging of many human malignancies.

Original languageEnglish (US)
Pages (from-to)1544-1550
Number of pages7
JournalCancer
Volume67
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Feasibility Studies
Heterografts
Positron-Emission Tomography
Glucose
Neoplasms
Melanoma
Renal Cell Carcinoma
Colonic Neoplasms
Electrons
Choriocarcinoma
Small Cell Lung Carcinoma
B-Cell Lymphoma
Neuroblastoma
Urinary Bladder Neoplasms
Nude Mice
Lymphoma
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wahl, R. L., Hutchins, G., Buchsbaum, D. J., Liebert, M., Barton Grossman, H., & Fisher, S. (1991). 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography. Cancer, 67(6), 1544-1550.

18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts : Feasibility studies for cancer imaging with positron-emission tomography. / Wahl, R. L.; Hutchins, Gary; Buchsbaum, D. J.; Liebert, M.; Barton Grossman, H.; Fisher, S.

In: Cancer, Vol. 67, No. 6, 1991, p. 1544-1550.

Research output: Contribution to journalArticle

Wahl, RL, Hutchins, G, Buchsbaum, DJ, Liebert, M, Barton Grossman, H & Fisher, S 1991, '18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography', Cancer, vol. 67, no. 6, pp. 1544-1550.
Wahl, R. L. ; Hutchins, Gary ; Buchsbaum, D. J. ; Liebert, M. ; Barton Grossman, H. ; Fisher, S. / 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts : Feasibility studies for cancer imaging with positron-emission tomography. In: Cancer. 1991 ; Vol. 67, No. 6. pp. 1544-1550.
@article{3a83758e5a48420d87d6fd23adca8956,
title = "18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography",
abstract = "The positron-emitting glucose analogue 18F-2-fluoro-2-deoxy-d-glucose (FDG) was evaluated for its accretion into the following subcutaneous human tumor xenografts in nude mice: B-cell lymphoma (Namalwa or Raji), ovarian carcinoma (HTB77), colon cancer (SW948), choriocarcinoma (BEWO), bladder cancer (UM-UC-2), renal cell carcinoma (UM-RC-3), neuroblastoma (Mey), melanoma (HTB63), and small cell lung carcinoma (NCI69). Two hours postinjection, tumor uptakes ranged from 0.027 (colon cancer) to 0.125{\%} kg injected dose/g (melanoma); and was greater than 0.085 in the Namalwa lymphomas and the renal cell carcinomas. Tumor-blood ratios of up to 23:1 were seen 2 hours postinjection (melanoma) with a mean tumor-blood ratio for all tumors of 12.3 ± 1.8. Uptake in the other tumors was intermediate. When evaluated, tumor uptake was slightly greater at 1 than at 2 hours postinjection, although target-background ratios were generally higher at 2 hours postinjection. This compound, FDG, may have broad applicability as a tracer for positron-emission tomographic imaging of many human malignancies.",
author = "Wahl, {R. L.} and Gary Hutchins and Buchsbaum, {D. J.} and M. Liebert and {Barton Grossman}, H. and S. Fisher",
year = "1991",
language = "English (US)",
volume = "67",
pages = "1544--1550",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts

T2 - Feasibility studies for cancer imaging with positron-emission tomography

AU - Wahl, R. L.

AU - Hutchins, Gary

AU - Buchsbaum, D. J.

AU - Liebert, M.

AU - Barton Grossman, H.

AU - Fisher, S.

PY - 1991

Y1 - 1991

N2 - The positron-emitting glucose analogue 18F-2-fluoro-2-deoxy-d-glucose (FDG) was evaluated for its accretion into the following subcutaneous human tumor xenografts in nude mice: B-cell lymphoma (Namalwa or Raji), ovarian carcinoma (HTB77), colon cancer (SW948), choriocarcinoma (BEWO), bladder cancer (UM-UC-2), renal cell carcinoma (UM-RC-3), neuroblastoma (Mey), melanoma (HTB63), and small cell lung carcinoma (NCI69). Two hours postinjection, tumor uptakes ranged from 0.027 (colon cancer) to 0.125% kg injected dose/g (melanoma); and was greater than 0.085 in the Namalwa lymphomas and the renal cell carcinomas. Tumor-blood ratios of up to 23:1 were seen 2 hours postinjection (melanoma) with a mean tumor-blood ratio for all tumors of 12.3 ± 1.8. Uptake in the other tumors was intermediate. When evaluated, tumor uptake was slightly greater at 1 than at 2 hours postinjection, although target-background ratios were generally higher at 2 hours postinjection. This compound, FDG, may have broad applicability as a tracer for positron-emission tomographic imaging of many human malignancies.

AB - The positron-emitting glucose analogue 18F-2-fluoro-2-deoxy-d-glucose (FDG) was evaluated for its accretion into the following subcutaneous human tumor xenografts in nude mice: B-cell lymphoma (Namalwa or Raji), ovarian carcinoma (HTB77), colon cancer (SW948), choriocarcinoma (BEWO), bladder cancer (UM-UC-2), renal cell carcinoma (UM-RC-3), neuroblastoma (Mey), melanoma (HTB63), and small cell lung carcinoma (NCI69). Two hours postinjection, tumor uptakes ranged from 0.027 (colon cancer) to 0.125% kg injected dose/g (melanoma); and was greater than 0.085 in the Namalwa lymphomas and the renal cell carcinomas. Tumor-blood ratios of up to 23:1 were seen 2 hours postinjection (melanoma) with a mean tumor-blood ratio for all tumors of 12.3 ± 1.8. Uptake in the other tumors was intermediate. When evaluated, tumor uptake was slightly greater at 1 than at 2 hours postinjection, although target-background ratios were generally higher at 2 hours postinjection. This compound, FDG, may have broad applicability as a tracer for positron-emission tomographic imaging of many human malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0025810148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025810148&partnerID=8YFLogxK

M3 - Article

C2 - 2001543

AN - SCOPUS:0025810148

VL - 67

SP - 1544

EP - 1550

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -